FDA Grants Fast Track Designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma

Invectys, Inc. announced the US FDA has granted Fast Track designation to its revolutionary product, IVS-3001, a CAR-T cell immunotherapy that targets the rarely exploited immune checkpoint and tumor-specific antigen known as HLA-G.